中國的Cervus and Cucumis Polypeptide市場分析
Investigation Report on China Cervus and Cucumis Polypeptide Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||333632|
|出版日期||內容資訊||英文 30 Pages
|中國的Cervus and Cucumis Polypeptide市場分析 Investigation Report on China Cervus and Cucumis Polypeptide Market, 2010-2019|
|出版日期: 2015年06月25日||內容資訊: 英文 30 Pages||
Cervus and Cucumis Polypeptide自從打入中國市場之後便急速成長。年度銷售額從2006年的1,000萬人民幣，成長到2014年的3億1,000萬人民幣，年複合成長率達到50％以上。
本報告提供中國的Cervus and Cucumis Polypeptide市場相關調查分析，提供您市場規模，市場佔有率，零售價格，主要製造商，市場預測等相關的系統性資訊。
According to statistics, the incidence of rheumatoid arthritis (RA) is 0.2%-0.36% and the number of cases is 5-10 million in China. With the ageing population in China, over 60% of elder people aged above 60 suffer from osteoarthritis, says a study. Patients with osteoarthritis typically show reduced mobility and life quality caused by joint pain, malformation and joint dysfunction.
First developed by Gloria Pharmaceuticals Co., Ltd, cervus and cucumis polypeptide is a sterile water solution made of extracted bones of Cervus Nippon Temmick and the dry mature seeds of Cucumis melo L. And it works well in rheumatism, RA, early healing of fracture, osteoarthritis, pain in waist and lower extremities as well as wound recovery.
Cervus and cucumis polypeptide develops fast after entering China, annual sales value rising from less than CNY 10 million in 2006 to CNY 310 million in 2014 and CAGR during this period exceeding 50%. Currently, cervus and cucumis polypeptide in the Chinese market all come from the following three companies: Gloria Pharmaceuticals Co., Ltd, Heilongjiang Dilong Pharmaceutical Co., Ltd and Heilongjiang Jiangshi Pharmaceutical Co., Ltd, among which Gloria Pharmaceuticals Co., Ltd has the largest market share of over 80% for sales value in 2014.
The ageing population in China keeps growing, people aged 60 and above amounting to 212.42 million and occupying 15.5% of the total population while people aged 65 and above amounting to 137.55 million and occupying 10.1% of the total population by the end of 2014. With the ageing population, the incidence of RA will continue to grow. Therefore the market size of cervus and cucumis polypeptide is expected to keep expanding in the next few years in China.
Readers can get at least the following information from this report:
The author suggests the following groups of people purchase this report:
4.1Market Share by Sales Value